New — The Inspection Record: the 483 Observation Library and the first article. Join free →

The Economic Case

The opportunity to prove a decision was sound is the moment you make it. Every other moment costs more.

Inspection exposure is an economics problem before it's a documentation problem — a small fixed cost now against an unbounded, unpredictable one later, paid at the worst possible time.

The Pattern

Investigators rarely challenge that a decision was made.

They challenge how it was authorized.

Across batch dispositions, CAPAs, deviations, change controls, and effectiveness checks, the recurring inspection question is the same:

"Why was this conclusion justified at the time it was made?"

That question is the pattern, not the exception. The gap is whether the file can still answer it — and most can't, because the reasoning was never written down.

The economics in one line: the same rationale costs more at every later moment. Cost of capturing the rationale — during the decision: minutes; six months later: days; during the CAPA: weeks; during FDA remediation: months plus consultants. The cost compounds over time.

What that last row actually involves

  1. 01
    The retrospective review. Comparable decisions across the prior 12–24 months pulled and re-examined, plus a CAPA, effectiveness verification, and an SOP revision.
  2. 02
    The reconstruction. Weeks to months of senior QA/RA time rebuilding rationale that no longer fully exists — backstopped by consultants at $300–500/hr. Six figures is a normal landing spot before anything escalates.
  3. 03
    The escalation. Warning letter, consent decree, import alert — and now you're into batch holds and delayed releases. That's revenue, not just labor.

What It Costs to Close It

$497 a decision. The program from $999/mo.

The record is captured in minutes, at the moment of decision — when the reasoning is free, because it's already in everyone's head.

You convert an open-ended remediation-and-enforcement exposure into a small, fixed, predictable line item.

A known price against an unbounded risk — the kind of trade a CFO already knows how to approve.

Weighed Against Every Alternative

A compliance executive has six realistic moves.

Here's the cost of each — and what it actually buys.

AlternativeTypical costWhat it producesThe gap it leaves
Do nothing — rely on the QMS + audit trail$0 nowThe action logged, not the reasoningThe full 483 exposure — six figures when it lands
Expand the eQMS (Veeva / MasterControl / SOLABS) with custom fields$50k–$250k+/yr license + CSV/configMore fields to fill, inconsistentlyStill no inspection-facing authorization artifact; adds validation burden
Bring in ex-FDA consultants / mock inspections$300–500/hr; $25k–$100k+ per engagementAdvice, templates, remediation plansReactive — not a record made at the moment of decision; doesn't scale
Add QA / documentation headcount$100k–$160k+/yr fully loadedA person chasing rationale after the factCan't be present at every decision; no standardized artifact
Build a custom decision-record systemMonths of dev + Part 11 validation + maintenanceMaybe, eventuallyHigh risk, slow, permanent maintenance line
Tighten SOPs + trainingLowA requirement on paperBehavior is uneven and unprovable — you find out it failed during the inspection
ComplianceWorxs$497/decision or from $999/moThe inspection-facing authorization record, at the moment of decisionSits above the QMS — no migration, no validation, no headcount

Every alternative falls into one of two camps — expensive and still doesn't produce the artifact, or cheap and doesn't work. CW is the only commercially available option designed specifically to produce an inspection-facing authorization record at the moment the decision is made. The argument isn't "this is the cheapest tool." It's that nothing else in the budget is built to close this gap.

The line your champion takes to the CFO

"For $999/mo, we make every inspection-critical decision defensible the moment it's made — instead of betting that a 483 won't put senior QA on a six-figure, multi-month reconstruction and stall our releases."

Before You Buy

The questions your team will ask.

The economics are above. Here's what clears the rest of procurement.

Operational

Sits above your existing QMS — no replacement, no migration, no new system to maintain, no added headcount. Start with one decision; a record takes hours, not a rollout.

Regulatory fit

Structured to meet ALCOA+ attributes. Designed to be maintained within your Part 11 environment — you hold the finished record in your own validated QMS, where your controls apply.

Validation

The qualified person makes and owns the decision; CW structures the record. It's not a system issuing GMP determinations. Apply your risk-based approach; supplier documentation on request.

Vendor & data

The finished record is exportable and yours — stored in your own system. CW isn't your system of record, so vendor continuity never touches records you've already produced.

Procurement & legal

Case files and the IRR transact via Stripe; the program runs on a standard agreement, Net 30. Governing law: Massachusetts.

Accountability

CW does not make, approve, or recommend regulatory decisions. Those remain the responsibility of the regulated organization and its authorized personnel.

The opportunity to prove it was sound is the moment you make it.